Home/Filings/4/0001645113-21-000094
4//SEC Filing

Benaim Ely 4

Accession 0001645113-21-000094

CIK 0001645113other

Filed

Aug 2, 8:00 PM ET

Accepted

Aug 3, 5:29 PM ET

Size

10.1 KB

Accession

0001645113-21-000094

Insider Transaction Report

Form 4
Period: 2021-07-30
Benaim Ely
Chief Medical Officer
Transactions
  • Exercise/Conversion

    Ordinary Shares

    2021-07-30$83.30/sh+651$54,22829,795 total
  • Sale

    Ordinary Shares

    2021-08-02$149.38/sh536$80,06728,608 total
  • Sale

    Ordinary Shares

    2021-07-30$158.96/sh651$103,48329,144 total
  • Exercise/Conversion

    Options to Buy Ordinary Shares

    2021-07-306513,253 total
    Exercise: $83.30Exp: 2029-07-30Ordinary Shares (651 underlying)
Footnotes (3)
  • [F1]Transaction was made pursuant to a Rule 10b-5-1 trading plan adopted by Dr. Benaim.
  • [F2]Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted stock units. This sale is mandated by the issuer's award agreement under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
  • [F3]Fully vested as of the date hereof.

Issuer

NovoCure Ltd

CIK 0001645113

Entity typeother

Related Parties

1
  • filerCIK 0001632237

Filing Metadata

Form type
4
Filed
Aug 2, 8:00 PM ET
Accepted
Aug 3, 5:29 PM ET
Size
10.1 KB